🇺🇸 FDA
Pipeline program

SRF617

SRF617-201

Phase 2 small_molecule terminated

Quick answer

SRF617 for Metastatic Castration-resistant Prostate Cancer is a Phase 2 program (small_molecule) at Arcus Biosciences with 1 ClinicalTrials.gov record(s).

Program details

Company
Arcus Biosciences
Indication
Metastatic Castration-resistant Prostate Cancer
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials